Literature DB >> 22263055

A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.

Giulia Pasello1, Giuseppe Altavilla, Laura Bonanno, Federico Rea, Adolfo Gino Favaretto.   

Abstract

Malignant pleural mesothelioma is an aggressive tumour with poor prognosis and short duration of response probably due to the high chemo-refractoriness. Multimodality treatment based on preoperative chemotherapy, surgery and adjuvant radiotherapy seems to be a feasible and effective therapeutic option in selected patients.We report on a case of pathological complete response in a patient affected by malignant pleural mesothelioma who was treated with four cycles of preoperative chemotherapy based on carboplatin plus pemetrexed followed by parietal pleurectomy and lung decortication. Carboplatin plus pemetrexed was a well tolerated regimen without grade 3-4 haematological toxicity, and this confirm the feasibility of such a treatment as an alternative to the current golden standard based on cisplatin plus pemetrexed.Complete resection allows the pathologist to better describe biological markers of mesothelioma cells, in order to select patients with different treatment outcome and prognosis.

Entities:  

Keywords:  carboplatin; chemotherapy; mesothelioma; pemetrexed

Year:  2010        PMID: 22263055      PMCID: PMC3256467          DOI: 10.3978/j.issn.2072-1439.2010.02.04.2

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  6 in total

1.  Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

Authors:  P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

2.  Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.

Authors:  Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori
Journal:  Lung Cancer       Date:  2007-04-02       Impact factor: 5.705

3.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

4.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Authors:  Giovanni L Ceresoli; Paolo A Zucali; Adolfo G Favaretto; Francesco Grossi; Paolo Bidoli; Guido Del Conte; Anna Ceribelli; Alessandra Bearz; Emanuela Morenghi; Raffaele Cavina; Maurizio Marangolo; Hector J Soto Parra; Armando Santoro
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

5.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

6.  Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.

Authors:  W Weder; R A Stahel; J Bernhard; S Bodis; P Vogt; P Ballabeni; D Lardinois; D Betticher; R Schmid; R Stupp; H B Ris; M Jermann; W Mingrone; A D Roth; A Spiliopoulos
Journal:  Ann Oncol       Date:  2007-04-11       Impact factor: 32.976

  6 in total
  1 in total

1.  Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.

Authors:  Paul Zarogoulidis; Maria Mavroudi; Konstantinos Porpodis; Kalliopi Domvri; Antonios Sakkas; Nikolaos Machairiotis; Aikaterini Stylianaki; Anastasios Tsiotsios; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  Onco Targets Ther       Date:  2012-09-27       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.